

4th International Meeting

# Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application


June 19–22, 2024 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Alizadeh	Ash	Adaptive Biotechnologies Corporation, CiberMed, Gilead Sciences Inc, Foresight Diagnostics, CARGO THERAPEUTICS, Foresight Diagnostics	IC, IC, IC, S, S, IC	Speaker
Amador	Catalina	No Relationships		Speaker
Apostolou	Effie	No Relationships		Speaker
Arthur	Ronald	No Relationships		Staff
Bertoni	Francesco	Phi Pharma, Patent , Helsinn Healthcare SA, Basilea Pharmaceutica, KoDiscovery, Menarini Ricerche, Curis, Polyphor	IC, P, GC, GC, GC, GC, GC, GC	Progam Committee, Speaker
Brody	Joshua	Bristol Myers Squibb Company, AstraZeneca, Seagen Inc., Kite Pharma, Inc., Epizyme, Inc., Merck	IC, IC, IC, IC, IC, IC	Speaker
Chaudhuri	Jayanta	No Relationships		Speaker
Crabtree	Gerald	foghorn therapeutics, Shenandoah therapeutics	IC, IC, SO	Speaker




4th International Meeting

# Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

June 19–22, 2024 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Flowers	Christopher	Pfizer Inc., Celgene Corporation, Spectrum Pharmaceuticals Inc., Ziopharm, Janssen Biotech, Inc., TG Therapeutics, Xencor, Sanofi, Adaptimmune, Pharmacyclics LLC, An AbbVie Company, Foresight Diagnostics, Epizyme, Inc., Celgene, N Power, Guardant, Collectis, Gilead Sciences Inc, AbbVie, Bayer, Novartis, Bayer, Genmab, Denovo Biopharma, Genentech USA, Inc., Seagen Inc., N Power, National Cancer Institute, AbbVie, Nektar, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research, Bayer, Kite Pharma, Inc., 4D, Karyopharm Therapeutics Inc., EMD, Foresight Diagnostics, Iovance, Acerta Pharma LLC, BeiGene USA, Inc., Morphosys, Amgen Inc., Pharmacyclics LLC, An AbbVie Company, Gilead Sciences, Inc., Burroughs Wellcome Fund, Allogene, Takeda Oncology, Genentech USA, Inc.	GC, GC, IC, GC, GC, GC, GC, GC, GC, IC, SO, IC, IC, SO, GC, GC, IC, GC, IC, GC, IC, IC, IC, GC, IC, IC, GC, IC, GC, GC, GC, GC, IC, GC, IC, GC, GC, IC, GC, GC, GC, GC, IC	Program Committee, Speaker
Giulino-Roth	Lisa	F. Hoffmann-La Roche AG, Merck, Seagen Inc.	IC, IC, IC	Speaker
Green	Michael	Allogene, Kite Pharma, Inc., Daiichi Sankyo Company, Monte Rosa Therapeutics, KDAc Therapeutics, SANOFI US SERVICES INC.	GC, GC, IC, IC, S, GC	Program Committee, Speaker
Gurumurthy	Aishwarya	No Relationships		Speaker
Horowitz	Steven	Abcuro Inc, Corvus, Daiichi Sankyo, March Bio, Daiichi Sankyo, Shoreline Biosciences, Trillium Therapeutics, Secura Bio Inc, Auxilius Pharma, Affimed, Secura Bio Inc, CRISPR Therapeutics, Pfizer, Takeda Pharmaceuticals, Autolus ltd, Celegne , Sym Bio, Kyowa Hakko Kirin, Dren Bio, Ono Pharmaceuticals, ADC Therapeutics, Seattle Genetics, Kyowa Kirin Co., Ltd, Takeda Pharmaceuticals	IC, IC, GC, IC, IC, IC, GC, IC, IC, GC, GC, GC, IC, IC, IC, GC, IC, GC, IC, IC, GC, GC, IC, GC	Speaker
Hutchings	Martin	Janssen Biotech, Takeda Oncology, AbbVie, Takeda Oncology, Incyte Corporation, Genmab, Merck, F. Hoffmann-La Roche, AbbVie, Novartis, Genmab, F. Hoffmann-La Roche, Genmab, Celgene	GC, GC, GC, IC, GC, IC, GC, IC, IC, GC, GC, GC, GC, GC	Speaker
Isshiki	Yusuke	No Relationships		Speaker
Li	Xubin	No Relationships		Speaker




4th International Meeting

# Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

June 19–22, 2024 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Lin	Wen-Hsuan Wendy	No Relationships		Speaker
Mak	Tak	Treadwell Therapeutics, Agios Pharmaceuticals, Inc., Tessa Therapeutics, Treadwell Therapeutics, AstraZeneca	IC, S, IC, SO, IC	Speaker
Melani	Christopher	No Relationships		Speaker
Melnick	Ari	Janssen Global Services, LLC, Treeline Biosciences, AstraZeneca UK Limited, Daiichi Sankyo Inc., Ipsen Bioscience Inc, Exscientia	IC, IC, IC, IC, IC, IC	Program Committee, Speaker
Mlynarczyk	Coraline	No Relationships		Speaker
Muppidi	Jagan	No Relationships		Speaker
Parente Calado	Dinis Pedro	Myricx Bio, AstraZeneca, Patent	SO, GC, P	Speaker
Parry	Erin	Patent, Patent	P, P	Speaker
Pasqualucci	Laura	AstraZeneca, AstraZeneca	GC, GC	Program Committee, Speaker
Portelinha	Ana	No Relationships		Speaker
Post	Dean	No Relationships		Staff
Radtke	Andrea	No Relationships		Speaker
Reinhardt	H. Christian	AstraZeneca, AbbVie	GC, IC	Speaker
Roulland	Sandrine	Bristol Myers Squibb Company	GC	Speaker
Ruella	Marco	Sana Biotherapeutics, Beckman Coulter, Inc., Bristol Myers Squibb Company, Lumicks, University of Pennsylvania, Bayer, ONI Inc., PeproMene, Gerson Lehrman Group, viTToria Biotherapeutics, GlaxoSmithKline, Curiox Biosystems, AbClon, viTToria Biotherapeutics, AbClon, viTToria Biotherapeutics	IC, GC, IC, GC, IC, IC, GC, IC, IC, IC, IC, GC, IC, IC, GC, GC	Speaker
Ruland	Jürgen	No Relationships		Speaker
Sadelain	Michel	Takeda Pharmaceutical Company, Mnemo Therapeutics	GC, P	Speaker
Sekar	Aswin	Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals	S, S	Speaker



4th International Meeting

# Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

June 19–22, 2024 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Shipp	Margaret	AstraZeneca, Bristol-Myers Squibb, Merck	GC, GC, GC	Program Committee, Speaker
Singh	Mandeep	No Relationships		Speaker
Venturutti	Leandro	No Relationships		Speaker
Westin	Jason	Janssen Biotech, Monta Rosa Therapeutics, Genmab, AbbVie, ADC Therapeutics, Iksuda Therapeutics, Morphosys, Bristol-Myers Squibb, Karyopharm Therapeutics, Incyte Corporation, Amgen, Novartis, Kite Pharma, Inc., Nurix, AstraZeneca, The University of Texas MD Anderson Cancer Center, Genentech, Umoja Biopharma, Inc., Merck	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, E, IC, IC, IC	Speaker
Zamponi	Nahuel	No Relationships		Speaker
Zappasodi	Roberta	Patent, Bristol-Myers Squibb	P, GC	Speaker
Zhao	Weili	No Relationships		Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.